Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company ...

By Kamal Choudhury (Reuters) -ITeos Therapeutics plans to wind down its operations and sell its assets, including experimental cancer treatments and an obesity drug, the company said on Wednesday, two ...

Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the market ...

Teos Therapeutics is throwing in the towel. | iTeos Therapeutics is throwing in the towel. Two weeks after axing its ...

Teos Therapeutics (ITOS) stock surges 25% as the company announces plans to wind down operations, focusing on shareholder ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Pharmaceutical share prices fell last Monday, after US President Donald Trump vowed to reduce drug prices in the USA by as ...

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

As of Thursday, May 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 5.79%, which has investors questioning if ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

At that time, I noted the potential of the company advancing its anti-TIGIT drug belrestotug together with GSK plc's (GSK) PD-1/PD-L1 JEMPERLI (dostarlimab) for the targeting of previously ...